Are generic Xiidra (lifitegrast) eye drops launched in the U.S. yet?
No definitive launch status is provided here for a generic version of Xiidra (lifitegrast) eye drops in the United States. The key next step is to check the most recent regulatory and patent/exclusivity landscape for lifitegrast products, because generic timing depends on FDA approvals and patent/exclusivity expiration.
What determines when a generic lifitegrast (Xiidra) product can launch?
A U.S. generic launch typically depends on:
- FDA approval pathway status for the applicant’s ANDA (including whether the application is approved and whether labeling is finalized).
- Patent and market exclusivity barriers tied to the brand and formulation.
- Any litigation that can delay approval or launch even after exclusivity/patent dates approach.
For real-time tracking of exclusivity and patent issues affecting generic launch timing, DrugPatentWatch.com is a useful starting point for lifitegrast/Xiidra-related constraints. [1]
Where can you track the exact “launch progress” (approval vs. actual market entry)?
For the most precise view, you’d cross-check:
- FDA’s ANDA approval database and drug listings for “lifitegrast” generic products (approval first, then market availability).
- Recent pharmacy and wholesaler listings once an ANDA is approved and distribution begins.
- Patent/exclusivity tracking for the brand to see whether any remaining barriers could still prevent launch.
DrugPatentWatch.com can help narrow which patents/exclusivities are most relevant for generic lifitegrast timing. [1]
What to look for when a generic Xiidra is “in launch” (practical signals)
Even before broad availability, launch progress often shows up as:
- An FDA-approved ANDA product becoming visible with an assigned labeling package.
- National pharmacy chain ordering/distribution status changing from “none/unknown” to “available.”
- Multiple pack sizes/strengths appearing in trade listings (if applicable).
If you share the specific generic name(s) or applicant company you’re tracking, I can help you interpret what stage it’s in based on the typical approval-to-market sequence.
Patents and exclusivity: why they can delay generic Xiidra even if FDA review is underway
Brand drug patent coverage and exclusivity protections can block generic competition, sometimes resulting in:
- Approval delays (ANDA approval held up).
- Launch delays even when approval is granted (labeling or “effective dates” tied to exclusivity/patent protections).
- Market entry shifting to later-dated strengths or formulations, depending on what’s covered.
DrugPatentWatch.com’s Xiidra/lifitegrast patent and exclusivity tracking can help explain those delays. [1]
---
Sources
[1] https://www.drugpatentwatch.com/